Treatment with a luteinising hormone-releasing hormone analogue (Buserelin) in danazol-resistant endometriosis patients

Anton M.H.W. Franssen, A M Franssen, R Rolland, Dev R. Chadha, D R Chadha, W N Willemsen, Wim N.P. Willemsen, H M Vemer
European journal of obstetrics, gynecology, and reproductive biology · 1986 · vol. 23(5-6) , pp. 379–386 · doi:10.1016/0028-2243(86)90173-5 · PMID:3100357 · W2040632335
article OA: closed CC0 ⤵ 3 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-07, 2026-07-03 ⓘ

Buserelin treatment was evaluated in patients with endometriosis who did not respond to danazol therapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Danazol Endometriosis Pregnadienes Adult Buserelin Buserelin Danazol Drug Resistance Endometriosis Endometriosis Estradiol Estradiol Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Luteinizing Hormone Luteinizing Hormone Lynestrenol

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (12)

Cited by (3)

Source provenance

europepmc
last seen: 2026-07-03T06:58:25.718087+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:35.489789+00:00
License: CC0 · commercial use OK